StockData
Evolus, Inc. logo

Evolus, Inc. (EOLS) stock

EOLSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$6.69+0.06 (+0.90%)

Close on Nov 17, 2026Market cap $441.88MP/E –Yield –

Evolus total debt

Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.

Evolus's total debt was $156.74M at Jun 30, 2026. For fiscal 2025 it was $146.10M, up 20.2% from the year before. The highest annual figure on record is $146.10M in fiscal 2025.

Annual total debt

PeriodPeriod endValueChange
FY2025Dec 31, 2025$146.10M+20.2%
FY2024Dec 31, 2024$121.51M+65.3%
FY2019Dec 31, 2019$73.51M–
FY2018Dec 31, 2018$0–
FY2017Dec 31, 2017$0–

Quarterly total debt

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$156.74M+7.7%
Q1 FY2026Mar 31, 2026$156.41M+28.7%
Q4 FY2025Dec 31, 2025$146.10M+97.0%
Q3 FY2025Sep 30, 2025$145.78M+97.4%
Q2 FY2025Jun 30, 2025$145.48M+97.9%
Q4 FY2024Dec 31, 2024$121.51M+66.0%
Q2 FY2020Jun 30, 2020$74.17M+1.8%
Q1 FY2020Mar 31, 2020$73.84M+1.8%
Q4 FY2019Dec 31, 2019$73.51M–
Q3 FY2019Sep 30, 2019$73.18M+335.8%
Q2 FY2019Jun 30, 2019$72.86M+342.4%
Q1 FY2019Mar 31, 2019$72.56M+349.3%
Q4 FY2018Dec 31, 2018$0–
Q3 FY2018Sep 30, 2018$16.79M–
Q2 FY2018Jun 30, 2018$16.47M–
Q1 FY2018Mar 31, 2018$16.15M–
Q4 FY2017Dec 31, 2017$0–

More Evolus figures

See a number that looks wrong?